☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Ipsen
Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors
July 2, 2024
Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis
June 11, 2024
Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Disease...
April 22, 2024
Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors
April 2, 2024
Ipsen’s Sohonos (palovarotene) Receives the US FDA’s Approval for Fibrodysplasia Ossificans Progressiva
August 16, 2023
Ipsen’s Bylvay (odevixibat) Receives the US FDA’s Approval for the Treatment of Cholestatic Pruritus Due to Alagille Syndrome
June 14, 2023
Load more...
Back to Home